A Phase 1 Study of PF-07799544 Plus PF-07799933 in People With BRAF V600-Mutated Advanced Melanoma

Full Title

A Phase 1A/B Open Label Master Study of PF 07799544 as a Single Agent and in Combination with other Targeted Agents in Participants with Advanced Solid Tumors

Purpose

Researchers want to find the best doses of PF-07799544 and PF-07799933 to use in people with advanced melanoma. The people in this study have melanoma that has metastasized (spread) and has a mutation (change) in the BRAF gene.

PF-07799544 and PF-07799933 both work by blocking proteins that promote melanoma growth. PF-07799544 blocks a family of proteins called MEK and PF-07799933 inhibits the BRAF protein. Both drugs are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have metastatic melanoma that has a BRAF mutation and cannot be successfully treated with existing medications.
• Have recovered from the serious side effects of prior therapies before taking the study drugs.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Monica Chen’s office at 646-888-5108.